Taiho Ventures

Founder and Managing Partner Sakae Asanuma chairs the investment committee, drawing on his tenure as President of Astellas Pharma US. Day-to-day deal sourcing and diligence is conducted by a core team spread across the Menlo Park, Princeton, and Abu Dhabi offices, blending pharmaceutical operational experience with institutional venture backgrounds.

The firm operates independently but maintains a strategic relationship with Taiho Pharmaceutical, a Japanese oncology-focused pharma company that is one of its capital partners. Taiho Ventures is not a captive corporate venture arm; it manages capital from multiple sources, including family offices and sovereign-linked entities, allowing it to pursue investments beyond the parent pharma's immediate pipeline priorities.

Taiho Ventures concentrates on early-stage companies, typically Seed through Series B, across North America and Europe with selective exposure in Asia. The firm focuses on therapeutics, digital health platforms, and AI-enabled drug discovery tools, often entering priced equity rounds alongside established biotech syndicates.

Taiho Ventures is structured for direct early-stage equity investments and spin-off financings. There is no public record of the firm allocating to third-party venture funds as a limited partner, reinforcing its posture as a direct, thesis-driven investor rather than a fund-of-funds allocator.

The firm actively co-invests alongside established life-science venture capital syndicates. Public filings show participation in rounds alongside Arch Venture Partners, venBio, and 5AM Ventures, indicating a collaborative rather than competitive stance with top-tier specialist funds.